NEXIEN BIOPHARMA, INC.: key financial figures for fiscal year 2024 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:
- Net Income/Loss (FY2024)
- -$239.1K
- Total Assets (FY2024)
- $4.2K
- Total Equity (FY2024)
- -$361.2K
- Cash Flows from Operating Activities (FY2024)
- -$64.4K
Source: NEXIEN BIOPHARMA, INC. 10-K filing (FY2024). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.
